

PATENT APPLICATION

TITLE

Use of N-octanoyl amino acids as slimming cosmetic and pharmaceutical active agent

APPLICANT

SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES
CHIMIQUES SEPPIC

INVENTORS

Christine GARCIA

ABSTRACT

Use of a compound of formula (I):



in which R_1 represents a hydrocarbon radical comprising 7 carbon atoms, R_2 represents the characterizing chain of an amino acid and m is between 1 and 50, or of a mixture of the said compounds of formula (I), as a slimming active agent. Nontherapeutic method of treatment using the said compound and use of the said compound for preparing a medicament with lipolytic activity, intended to induce slimming of the human body.

The subject of the present invention is a novel use of cosmetic active agents for slimming the human body.

Some of the fat in the human body is stored in the form
5 of triglycerides, in cells of the fatty tissue of the dermis, called adipocytes. Slimming reflects a reduction in the fat stored in the adipocytes. This process requires a preliminary step which takes place inside these cells and which consists in hydrolysing
10 the triglycerides to fatty acids and glycerol. This phenomenon is called lipolysis.

Most slimming cosmetic formulations currently marketed contain at least one compound possessing a lipolytic
15 activity. The one most frequently used is caffeine, but theophylline is also known to possess such a property.

During their search for novel active agents with lipolytic activity which have better compatibility with
20 the skin than those of the state of the art, the inventors demonstrated that certain N-acylated derivatives of amino acids known for their soothing property also had a lipolytic property which was more effective than that of caffeine.

25

Accordingly, according to a first aspect, the subject of the invention is the use of a compound of formula (I):



30

L — J

in which R₁ represents a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical comprising 7 carbon atoms, R₂ represents the
35 characterizing chain of an amino acid and m is between 1 and 50, or of a mixture of the said compounds of formula (I), as a slimming active agent, in a

composition containing a cosmetically acceptable medium.

The compound of formula (I) as defined above may be in
5 the form of a free acid or in a partially or completely
salified form. When the compound of formula (I) is in a
salified form, it comprises in particular alkali metal
salts such as the sodium, potassium or lithium salts,
10 alkaline-earth metal salts such as the calcium,
magnesium or strontium salts; an ammonium salt or a
salt of an amino alcohol such as the (2-hydroxyethyl)-
ammonium salt. It may also comprise metal salts such as
divalent zinc or manganese salts, trivalent iron,
15 lanthanum, cerium or aluminium salts. In general, the
degree of salification of the compound of formula (I)
as defined above will additionally depend on its pK_A
and the salt concentration of the composition into
which it is incorporated.

20 In the following disclosure, the expression compound of
formula (I) is understood to mean a compound of formula
(I) in free form or in a partially or completely
salified form.

25 The expression "characterizing chain" used to define
the radical R_2 denotes the nonfunctional principal
chain of the amino acid considered.

Thus, for an amino acid represented by general formula
30 (IIIa):



and for a cyclic amino acid represented by formula
35 (IIIb):




the characterizing chain will be the chain represented by R₂.

R₂ represents in particular the characterizing chain of
5 an amino acid chosen from glycine, alanine, serine,
aspartic acid, glutamic acid, valine, threonine,
arginine, lysine, proline, leucine, phenylalanine,
isoleucine, histidine, tyrosine, tryptophan,
10 asparagine, glutamine, cysteine, cystine, methionine,
hydroxyproline, hydroxylysine, sarcosine or ornithine.

The subject of the invention is mainly the use of a compound of formula (I) as defined above, in which, in the residue:

15



R₂ represents the characterizing chain of glycine.

20 The subject of the invention is more particularly the use of a compound of formula (I) as defined above, in which m is a decimal number between 1 and 10 and it is preferably less than 5.

25 According to a most particular aspect of the present invention, in formula (I) as defined above, m is less than or equal to 2 and is more particularly less than or equal to 1.4.

30 According to another most particular aspect of the present invention, in formula (I) as defined above, m is equal to 1.

35 According to another particular variant of the present invention, a single compound of formula (I) as defined above is used in the composition containing the cosmetically acceptable medium.

According to another particular variant of the present invention, a mixture of compounds of formula (I) as defined above is used.

5 The compounds of formulae (I) are generally obtained by N-acylation of compounds of formulae (IIIA) or (IIIB), as defined above, or their salts.

In the case of a mixture of compounds of formulae (I)
10 it is for example obtained by N-acylation of the mixture of amino acids resulting from the total or partial hydrolysis of proteins of any origin.

These proteins may be of animal origin, such as for
15 example collagen, elastin, fish flesh protein, fish gelatin, keratin or casein, of plant origin, such as cereal, flower or fruit proteins such as for example the proteins derived from soya bean, sunflower, oats, wheat, maize, barley, potato, lupin, field bean, sweet
20 almond, kiwi, mango or apple; they may also be proteins obtained from Chorella (unicellular algae), pink algae, yeasts or silk.

This hydrolysis is carried out, for example, by heating
25 to temperatures of between 60 and 130°C a protein placed in an acidic or alkaline medium.

This hydrolysis may also be carried out enzymatically, with a protease, optionally coupled with a post-
30 alkaline or post-acid hydrolysis. When m is greater than 1, R₂ represents a single chain or several chains characterizing different amino acids, depending on the protein hydrolysed and the degree of hydrolysis.

35 The aminograms of a few proteins of plant origin are presented in the following tables:

Table 1

	Origin of the protein (proportions of amino acids expressed in wt %)			
	Oats	Soya bean	Wheat	Sunflower
Glycine	6.9	4.2	3.2	6.2
Alanine	5.9	4.2	2.6	4.8
Serine	5.6	5.1	1.7	5.1
Aspartic acid	16.2	11.7	3.4	10.6
Glutamic acid	28.3	19.1	37.9	23.6
Valine	2.9	5.0	4.2	4.8
Threonine	3.1	3.9	2.7	4.4
Arginine	6.6	7.8	3.7	8.4
Lysine	3.6	6.2	1.9	3.2
Proline	4.7	5.4	11.7	3.0
Leucine	6.4	8.1	7.1	6.4
Phenylalanine	1.4	5.0	5.4	4.3
Isoleucine	2.2	4.8	3.7	4.1
Histidine	1.7	2.6	2.4	2.0
Tyrosine	1.5	3.5	3.1	2.7
Methionine	1.2	1.2	1.6	1.8
Cysteine/cystine	1.9	1.5	1.9	1.9
Tryptophan	-	1.0	1.0	1.3

Table 2

	Origin of the protein (proportions of amino acids expressed in wt %)			
	Lupin	Potato	Field bean	Maize
Glycine	0.9	4.8	4.0	2.4
Alanine	2.4	5.0	4.0	7.95
Serine	6.1	5.8	4.9	5.1
Aspartic acid	15.8	12.5	10.5	10.6
Glutamic acid	8.0	11.5	16.8	23.6
Valine	7.9	7.1	4.5	4.8
Threonine	8.1	6.1	3.6	4.4

Arginine	16.1	5.0	9.21	8.4
Lysine	7.1	7.8	6.5	6.2
Proline	-	5.1	4.4	3.0
Leucine	7.45	10.4	7.4	8.1
Phenylalanine	8.6	6.4	4.4	4.3
Isoleucine	8.7	6.1	3.9	4.1
Histidine	-	2.2	2.6	2.0
Tyrosine	-	5.7	3.6	2.7
Methionine	0.6	2.4	0.8	1.8
Cysteine/cystine	-	1.6	1.7	1.9
Tryptophan	1.2	1.4	1.2	1.3
Ornithine	0.4	-	-	-

The acylation reaction is known to persons skilled in the art. It is described for example in international application published under the number WO 98/09611. It
5 is carried out indifferently on an amino acid or on a mixture of amino acids. The acylating agent generally consists of an activated derivative of a carboxylic acid of formula $R_1-C(=O)-OH$, in which R_1 is as defined above, such as a symmetric anhydride of this acid, the
10 methyl ester of this acid, or an acid halide such as the acid chloride or the acid bromide.

The subject of the invention is also a nontherapeutic method of treating the human body intended for slimming it, characterized in that a composition containing a cosmetically acceptable medium and an effective quantity of at least one compound of formula (I) as defined above, is applied to it.

20 The subject of the invention is also the use of at least one compound of formula (I), as defined above, for preparing a medicament with lipolytic activity, intended for inducing slimming of the human body.

25 In the compositions defined above, the compound of formula (I) is generally used in a quantity of between

0.01% and 10% of their weight, more particularly between 0.1% and 5% of their weight, and most particularly between 1% and 5% of their weight.

5 As the examples show, the compounds used in the cosmetic or therapeutic treatments defined above are characterized, unexpectedly, by a lipolytic activity greater than the compositions of the state of the art.
10 They are therefore in general appropriate for the slimming treatments of the human body.

The compositions used in the said treatments are generally provided in the form of dilute aqueous or aqueous-alcoholic solutions, in the form of simple or
15 multiple emulsions, such as water-in-oil (W/O), oil-in-water (O/W) or water-in-oil-in-water (W/O/W) emulsions in which the oil is of a vegetable or mineral nature, or in powdered form. They may also be dispersed or impregnated onto textile or onto nonwoven materials
20 such as wipes, paper serviettes or clothing.

The compositions used in the said treatments are administered to the subject in the conventional forms used in cosmetics and in pharmacy; this includes more
25 particularly topical, oral or parenteral administrations.

In general, the compounds of formula (I) are combined with many types of adjuvants or active ingredients used
30 in cosmetic formulations, such as fatty substances, organic solvents, thickeners, gelling agents, emollients, antioxidants, opacifiers, stabilizers, foaming agents, perfumes, emulsifiers, which are ionic or nonionic, fillers, sequestrants, chelators,
35 preservatives, chemical screening agents or inorganic screening agents, essential oils, colouring matter, pigments, hydrophilic or lipophilic active agents, humectants, for example glycerin, preservatives, colorants, perfumes, cosmetic active agents, inorganic

or organic sunscreens, inorganic fillers such as iron oxides, titanium oxides and talc, synthetic fillers such as nylons and poly(methyl methacrylate) which are crosslinked or otherwise, silicone elastomers,
5 sericites or plant extracts or alternatively lipid vesicles or any other ingredient customarily used in cosmetics.

As examples of oils which may be combined with the compound of formula (I), there may be mentioned mineral oils such as paraffin oil, liquid paraffin, isoparaffins or white mineral oils, oils of animal origin, such as squalene or squalane, vegetable oils, such as sweet almond oil, copra oil, castor oil, jojoba
15 oil, olive oil, rapeseed oil, groundnut oil, sunflower oil, wheat germ oil, maize germ oil, soya bean oil, cottonseed oil, lucerne oil, poppy seed oil, pumpkinseed oil, evening primrose oil, millet oil, barley oil, rye oil, safflower oil, candlenut oil,
20 passionflower oil, hazelnut oil, palm oil, shea butter, apricot kernel oil, calophyllum oil, sysymbrium oil, avocado oil, calendula oil; ethoxylated vegetable oils; synthetic oils such as fatty acid esters such as butyl myristate, propyl myristate, cetyl myristate, isopropyl
25 palmitate, butyl stearate, hexadecyl stearate, isopropyl stearate, octyl stearate, isocetyl stearate, dodecyl oleate, hexyl laurate, propylene glycol dicaprylate, esters derived from lanolic acid, such as isopropyl lanolate, isocetyl lanolate, monoglycerides,
30 diglycerides and triglycerides of fatty acids such as glyceryl triheptanoate, alkyl benzoates, poly-alpha-olefins, polyolefins such as polyisobutene, synthetic isoalkanes such as isohexadecane, isododecane, perfluorinated oils and silicone oils. Among the latter,
35 there may be mentioned more particularly dimethylpolysiloxanes, methylphenylpolysiloxanes, silicones modified with amines, silicones modified with fatty acids, silicones modified with alcohols, silicones modified with alcohols and fatty acids, silicones

modified with polyether groups, epoxy-modified silicones, silicones modified with fluorinated groups, cyclic silicones and silicones modified with alkyl groups.

5

As other fatty substances which may be combined with this active agent, there may be mentioned fatty alcohols or fatty acids.

10 Among the thickening and/or emulsifying polymers used in the present invention are for example homopolymers or copolymers of acrylic acid or of acrylic acid derivatives, homopolymers or copolymers of acrylamide, homopolymers or copolymers of acrylamide derivatives,
15 homopolymers or copolymers of acrylamidomethylpropane-sulphonic acid, vinyl monomer, trimethylaminooethyl-acrylate chloride, hydrocolloids of plant or biosynthetic origin, for example xanthan gum, karaya gum, carrageenans, alginates; silicates; cellulose and
20 its derivatives; starch and its hydrophilic derivatives; polyurethanes. Among the polymers of the polyelectrolyte type which may be used in the production of a gelled aqueous phase capable of being used in the preparation of W/O emulsions containing the
25 compounds of formula (I) which are the subject of the present invention, there are for example copolymers of acrylic acid and 2-methyl-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid (AMPS), copolymers of acrylamide and 2-methyl-[(1-oxo-2-propenyl)amino]-1-propane-
30 sulphonic acid, copolymers of 2-methyl-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid and (2-hydroxyethyl) acrylate, homopolymer of 2-methyl-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid, homopolymer of acrylic acid, copolymers of acryloyl-
35 ethyltrimethylammonium chloride and acrylamide, copolymers of AMPS and vinylpyrrolidone, copolymers of acrylic acid and alkyl acrylates whose carbon chain comprises between ten and thirty carbon atoms, copolymers of AMPS and alkyl acrylates whose carbon

chain comprises between ten and thirty carbon atoms. Such polymers are marketed respectively under the names SIMULGEL™ EG, SEPIGEL™ 305, SIMULGEL™ NS, SIMULGEL™ 800 and SIMULGEL™ A by the applicant.

5

Among the waxes which can be used in the present invention, there may be mentioned for example beeswax; carnauba wax, candelilla wax; ouricoury wax; Japan wax; cork fibre or sugarcane wax; paraffin waxes; lignite waxes; microcrystalline waxes; lanolin wax; ozokerite; polyethylene wax; hydrogenated oils; silicone waxes; vegetable waxes; fatty alcohols and fatty acids which are solid at room temperature; glycerides which are solid at room temperature. Among the emulsifiers which can be used in the present invention, there may be mentioned for example fatty acids, ethoxylated fatty acids, fatty acid esters of sorbitol, ethoxylated fatty acid esters, polysorbates, polyglycerol esters, ethoxylated fatty alcohols, sucrose esters, alkyl polyglycosides, sulphated and phosphated fatty alcohols or mixtures of alkyl polyglycosides and fatty alcohols described in French Patent Applications 2 668 080, 2 734 496, 2 756 195, 2 762 317, 2 784 680, 2 784 904, 2 791 565, 2 790 977, 2 807 435 and 2 804 432.

25

As examples of an active ingredient which may be combined with the compound of formula (I) there may be mentioned compounds having a lightening or depigmenting action, such as for example arbutin, kojic acid, hydroquinone, ellagic acid, vitamin C, magnesium ascorbyl phosphate, extracts of polyphenols, grape extracts, pine extracts, wine extracts, olive extracts, marc extracts, N-acylated proteins, N-acylated peptides, N-acylated amino acids, partial hydrolysates of N-acylated proteins, amino acids, peptides, total hydrolysates of proteins, partial hydrolysates of proteins, polyols (for example glycerin or butylene glycol), urea, pyrrolidonecarboxylic acid or derivatives of this acid, glycyrrhetic acid, alpha-

bisabolol, sugars or sugar derivatives, polysaccharides or their derivatives, hydroxy acids, for example lactic acid, vitamins, vitamin derivatives such as retinol, vitamin E and its derivatives, minerals, enzymes, 5 coenzymes such as Coenzyme Q10, hormones or hormone-like substances, soya bean extracts, for example Raffermine™, wheat extracts, for example Tensine™ or Gliadine™, vegetable extracts such as extracts rich in tannins, extracts rich in isoflavones or extracts rich 10 in terpenes, extracts of fresh water or marine algae, essential waxes, bacterial extracts, minerals, lipids in general, lipids such as ceramides or phospholipids, active agents having a slimming action such as caffeine or its derivatives, active agents having an 15 antimicrobial activity or a purifying action in relation to greasy skins such as LIPACIDE™ PVB, active agents having an energizing or stimulating property such as SEPITONIC™ M3 or Physiogenyl™, panthenol and its derivatives such as SEPICAP™ MP, antiageing active 20 agents such as SEPILIFT™ DPHP, LIPACIDE™ PVB, SEPIVINOL™, SEPIVITAL™, moisturizing active agents such as SEPICALM™ S, SEPICALM™ VG and LIPACIDE™ DPHP, "antiphotoageing" antiageing active agents, active agents protecting the integrity of the dermoepidermal 25 junction, active agents increasing the synthesis of the components of the extracellular matrix, active agents having a slimming, toning or draining activity such as caffeine, theophylline, cAMP, green tea, sage, ginko biloba, ivy, horse-chestnut, bamboo, ruscus, butcher's 30 broom, centella asiatica, heather, meadowsweet, fucus, rosemary, willow, active agents creating a sensation of "heat" on the skin, such as activators of skin microcirculation (for example nicotinates) or products creating a sensation of "freshness" on the skin (for 35 example menthol and its derivatives).

As sunscreen which may be incorporated into the composition according to the invention, there may be

mentioned all those which appear in the amended cosmetics directive 76/768/EEC, annex VII.

5 The following experimental study illustrates the invention without, however, limiting it.

A) Evaluation in vitro of the lipolytic activity of the compounds of formula (I)

10 (1) - Aim and principle of the method

The objective of the experiment is to demonstrate, in an in vitro model of isolated human adipocytes, the lipolytic activity of the compounds used. This is because triglycerides are stored in the adipocytes and constitute the fat reserve. For this reserve to diminish, which is the desired aim when slimming products are used, the triglycerides must be hydrolysed so that the fatty acids can be removed from the cell.
20 Hydrolysis of the triglycerides to nonesterified fatty acids and glycerol is called lipolysis.

The method described consists in incubating the products in the presence of human adipocytes in suspension, followed by the measurement of the nonesterified fatty acid level in the adipocyte incubation medium. The free fatty acid level thus reflects the hydrolysis of the triglycerides present in the adipocytes.
30

(2) - Experimental protocol

(i) Cellular model:

35 The test is carried out using human adipocytes isolated and prepared as a cellular suspension. The adipocytes are isolated from the subcutaneous abdominal adipose tissue recovered during plastic surgery operations (abdominal plastic surgery operations) performed on

women. The cells are isolated from fresh tissue. The adipose tissue is isolated and dissociated by the action of a collagenase (SIGMA™, 1 mg/ml, 30 minutes at 37°C, gentle stirring). Collagenase digests the connective tissue present in the adipose tissue. After digestion, the cells are filtered and washed in an appropriate culture medium containing MEM medium free of phenol red, free of glutamine (SIGMA) + 2.2 mg/ml of sodium bicarbonate (GIBCO) + 50 IU of penicillin (BIOWHITTAKER™) + 50 µg/ml of streptomycin (BIOWHITTAKER™) + 1% (v/v) of L-glutamine (BIOWHITTAKER™) + 0.5% of lipid-free serum albumin (SIGMA™). The adipocyte suspension is used immediately after its preparation.

15

(ii) Incubation of the products with the adipocytes

The test products are diluted in the adipocyte culture medium. They are incubated with the cells in suspension for two hours at 37°C (250 µl of product + 250 µl of adipocyte suspension).

25

(3) - Evaluation of the results

After the incubation, the cell lysis is checked visually by the presence of a lipid layer at the surface of the cellular suspension. The supernatant media are collected. The free fatty acids are assayed by spectrophotometry using a commercial kit (NEFA™ C kit, WAKO), with reference to a fatty acid calibration series. The lipolytic activity of the products is evaluated relative to a control group incubated in the presence of adipocytes and in the absence of product. The reactivity of the adipocytes is systematically checked for the measurement of the lipolytic activity of the reference products, caffeine (1,3,7-trimethyl-xanthine) and theophylline (1,3-dimethyl-2,6-dihydroxy-purine). Five assays are performed for each of the test

products. The lipolytic activity of LIPACIDE™ C8G, which contains active material 100% N-octanoylglycine, was thus evaluated.

5 The results of the trials, expressed by the arithmetic means of the five assays carried out for each of the products, are presented in the following table:

	Incubation concentration (wt %/volume)	Free fatty acid concentration (μ M)	Lipolytic activity (compared with the control = 100)
Control	-	11.54 \pm 2.71	100
Caffeine	0.0019	15.10 \pm 4.11	131
Theophylline	0.0019	16.53 \pm 4.23	143
LIPACIDE™ C8G	0.0001	23.83 \pm 5.11	206
LIPACIDE™ C8G	0.0005	25.30 \pm 2.70	219
LIPACIDE™ C8G	0.0010	25.75 \pm 0.86	223

10 These results show that while the slimming compositions of the state of the art (caffeine and theophylline) act on lipolysis with a multiplication factor of 1.3 to 1.4 relative to the control, that according to the invention, that is to say comprising at least one compound of formula (I) as defined above, acts with a factor of 2.06 to 2.23 at lower concentrations.

15

B) - Examples of cosmetic formulations

20 In the following examples, the proportions are expressed as percentages by weight.

Example 1: Slimming body milk

MONTANOV™ L	3.00%
Phytosqualane	8.00%
Sweet almond oil	2.00%

Water	qsp 100%
SEPIGEL™ 501	1.50%
LIPACIDE™ C8G	3.00%
SEPICIDE™ CI	0.20%
SEPICIDE™ HB	0.30%
Perfume	0.30%

Example 2: Anti-sagging cream (oval target of the face)

MONTANOV™ 202	3.50%
MONTANOV™ 14	1.00%
SEPILIFT™ DPHP	1.00%
LANOL™ 1688	15.00%
Wheat germ oil	5.00%

Water	qsp 100%
SIMULGEL™ EG	1.30%
LIPACIDE™ C8G	2.00%
SEPICIDE™ CI	0.20%
SEPICIDE™ HB	0.30%
Perfume	0.10%

Example 3: Anti-plumpness spray

MONTANE™ 60	3.30%
MONTANOX™ 60	1.70%
Caprylic/capric triglycerides	6.00%
Isohexadecane	5.00%

Magnesium Aluminium Silicate	1.50%
Water	qsp 100%

SIMULGEL™ EG	1.00%
--------------	-------

LIPACIDE™ C8G	2.00%
---------------	-------

Centalla asiatica/hydrocotyle extract	1.00%
SEPICIDE™ CI	0.20%
SEPICIDE™ HB	0.30%
Perfume	0.40%
Water	qsp 100%

Example 4: Refreshing slimming gel

SEPIGEL™ 305	3.50%
Hydroxyethylcellulose	1.00%
Caffeine	5.00%
Menthol	0.30%
Ethanol	50.00%
LIPACIDE™ C8G	3.00%
SEPICIDE™ LD	1.00%
Perfume	0.20%
Water	qsp 100%

Example 5: Slimming body fluid

SIMULGEL™ NS	2.50%
Xanthan gum	0.20%
LANOL™ 99	5.00%
LIPACIDE™ C8G	2.00%
Ginkgo biloba extract	2.00%
Cola extract	1.00%
Ginseng extract	0.50%
SEPICIDE™ HB	1.50%
Perfume	0.10%
Water	qsp 100%

5

Example 6: Toning revitalizing lotion intended to be impregnated into body wipes

LIPACIDE™ C8G	1.50%
Glycerin	5.00%
Ethanol	5.00%
Ruscus extract	3.00%
SEPITONIC™ M3	1.00%

SEPICIDE™ CI	0.20%
SEPICIDE™ HB	0.30%
Water	qsp 100%

Example 7: Slimming shower gel

MONTALINE™ C40	8.00%
PROTEOL™ OAT	5.00%
Sodium lauryl sulphate	9.00%
LIPACIDE™ C8G	3.00%
Green tea extract	1.00%
KATHON™ CG	0.80
Green colorant	qs
Green tea perfume	1.00%
Lactic acid	qs pH=6.5
Water	qsp 100%

Example 8: Biphasic disinfiltrating massage

Arabic coffee oil	1.00%
LANOL™ 189	20.00%
LANOL™ 99	10.00%
Borage oil	2.00%
Perfume	0.10%
LIPACIDE™ C8G	3.00%
Glycerin	3.00%
Ethanol	10.00%
Blue colorant	qs
Water	qsp 100%

The definitions of the commercial products used in the
5 examples are the following:

SEPILIFT™ DPHP: (INCI name: Dipalmitoyl hydroxyproline), marketed by the company SEPPIC;

SEPICIDE™ CI: Imidazoline urea (preservative), marketed by the company SEPPIC;

10 SEPICIDE™ HB: Mixture of phenoxyethanol, methylparaben, ethylparaben, propylparaben and butylparaben (preservative), marketed by the company SEPPIC;

SEPICIDE™ LD: Phenoxyethanol marketed by the company SEPPIC;

KATHON™ CG: (INCI name: methyl isothiazolinone / Methyl chloroisothiazolinone);

5 MONTANE™ 60: Sorbitan stearate;

MONTANOX™ 60: Polysorbate 60;

SIMULGEL™ EG: Self-reversible invert latex of copolymer such as those described in international publication WO 99/36445 (INCI name: Sodium acrylate/Sodium

10 acryloyldimethyl taurate copolymer and Isohexadecane and Polysorbate 80) marketed by the company SEPPIC;

SIMULGEL™ NS: Self-reversible invert latex of copolymer such as those described in international publication WO 99/36445 (INCI name: hydroxyethylacrylate/Sodium

15 acryloyldimethyl taurate copolymer and squalane and Polysorbate 60) marketed by the company SEPPIC;

SEPIGEL™ 305: Self-reversible invert latex (INCI name: Polyacrylamide / C13-14 Isoparaffin / Laureth-7);

SEPIGEL™ 501: Self-reversible invert latex INCI name:

20 C13-14 Isoparaffin/Mineral Oil/Sodium polyacrylate-/Polyacrylamide/Polysorbate 85;

LANOL™ 99: Isononyl isononanoate marketed by the company SEPPIC;

25 LANOL™ 189: Isostearyl isononanoate

LANOL™ 1688: Cetearyl ethyl hexanoate marketed by the company SEPPIC;

SEPITONIC™ M3: Mixture of magnesium aspartate, copper gluconate and zinc gluconate marketed by the company SEPPIC;

30 MONTALINE™ C40: Cocamidopropyl betainamide MEA chloride

PROTEOL™ OAT: Sodium Lauroyl oat amino acids;

MONTANOV™ 14: Myristyl alcohol / Myristyl glucoside;

MONTANOV™ L: Emulsifying agent based on a C14-C22 alcohol and a C12-C20 alkyl polyglucoside such as those

35 described in European Patent Application EP 0 995 487;

MONTANOV™ 202 is an emulsifying agent based on arachidyl alcohol, behenyl alcohol and arachidyl polyglucoside.